(Q34967095)

English

Gefitinib

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

5 August 2017

1 reference

Europe PubMed Central

Gefitinib. (English)

1 reference

Europe PubMed Central

5 August 2017

author name string

Christine R Culy

1

1 reference

Europe PubMed Central

5 August 2017

Diana Faulds

2

1 reference

Europe PubMed Central

5 August 2017

publication date

1 January 2002

1 reference

Europe PubMed Central

5 August 2017

1 reference

Europe PubMed Central

5 August 2017

62

1 reference

Europe PubMed Central

5 August 2017

2237-48; discussion 2249-50

1 reference

Europe PubMed Central

5 August 2017

15

1 reference

Europe PubMed Central

5 August 2017

https://scigraph.springernature.com/pub.10.2165/00003495-200262150-00008

0 references

Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase

1 reference

https://pubmed.ncbi.nlm.nih.gov/12381224

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12381224

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tyrosine kinase inhibitors-ZD1839 (Iressa).

1 reference

https://pubmed.ncbi.nlm.nih.gov/12381224

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/12381224

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/12381224

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor

1 reference

https://pubmed.ncbi.nlm.nih.gov/12381224

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The ErbB signaling network: receptor heterodimerization in development and cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/12381224

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines

1 reference

https://pubmed.ncbi.nlm.nih.gov/12381224

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12381224

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12381224

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12381224

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers

1 reference

https://pubmed.ncbi.nlm.nih.gov/12381224

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Iressa (ZD1839) in an EGFR-expressing multidrug-resistant cell line in vitro and in vivo

1 reference

https://pubmed.ncbi.nlm.nih.gov/12381224

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments

1 reference

https://pubmed.ncbi.nlm.nih.gov/12381224

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The epidermal growth factor receptor and its inhibition in cancer therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/12381224

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12381224

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lung cancer: a review

1 reference

https://pubmed.ncbi.nlm.nih.gov/12381224

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

ZD1839 ('Iressa') as an anticancer agent

1 reference

https://pubmed.ncbi.nlm.nih.gov/12381224

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reporting results of cancer treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/12381224

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/12381224

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/12381224

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition

1 reference

https://pubmed.ncbi.nlm.nih.gov/12381224

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Epidermal growth factor-related peptides and their receptors in human malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/12381224

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/00003495-200262150-00008

1 reference

Europe PubMed Central

5 August 2017

Dimensions Publication ID

0 references

release_7s444w7pefdinlkuqwe4rl22cy

1 reference

https://api.fatcat.wiki/v0/release/7s444w7pefdinlkuqwe4rl22cy

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

5 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34967095&oldid=1975337638"